Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Study of Darolutamide and Abemaciclib in High-Risk Prostate Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05617885
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:19.940949+00:00
Published At
2026-02-27T00:00:00+00:00
Record Updated At
2026-02-27
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Metastatic Prostate Cancer", "Non-metastatic Prostate Cancer", "Prostate Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-02-27"
protocolSection.identificationModule.nctId
"NCT05617885"
protocolSection.identificationModule.officialTitle
"A Phase 1/2 Study of Darolutamide and Abemaciclib in High-Risk Prostate Cancer"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Metastatic Prostate Cancer (protocolSection.conditionsModule.conditions)
  • Non-metastatic Prostate Cancer (protocolSection.conditionsModule.conditions)
  • Prostate Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.